S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
pixel
Demand for grocery delivery cools as food costs rise
Musk says Twitter deal could move ahead with 'bot' info
Dems' climate, energy, tax bill clears initial Senate hurdle
pixel
Shift in war's front seen as ships cleared to leave Ukraine
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
pixel
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
pixel
Demand for grocery delivery cools as food costs rise
Musk says Twitter deal could move ahead with 'bot' info
Dems' climate, energy, tax bill clears initial Senate hurdle
pixel
Shift in war's front seen as ships cleared to leave Ukraine
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
pixel
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
pixel
Demand for grocery delivery cools as food costs rise
Musk says Twitter deal could move ahead with 'bot' info
Dems' climate, energy, tax bill clears initial Senate hurdle
pixel
Shift in war's front seen as ships cleared to leave Ukraine
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
pixel
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
pixel
Demand for grocery delivery cools as food costs rise
Musk says Twitter deal could move ahead with 'bot' info
Dems' climate, energy, tax bill clears initial Senate hurdle
pixel
Shift in war's front seen as ships cleared to leave Ukraine
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
pixel
NASDAQ:ARTL

Artelo Biosciences (ARTL) Stock Forecast, Price & News

$0.38
0.00 (0.00%)
(As of 08/5/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.35
▼
$0.38
50-Day Range
$0.30
▼
$0.38
52-Week Range
$0.28
▼
$1.32
Volume
310,872 shs
Average Volume
245,405 shs
Market Capitalization
$15.95 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.50

Artelo Biosciences MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
828.4% Upside
$3.50 Price Target
Short Interest
Healthy
2.10% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.21) to ($0.22) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.81 out of 5 stars

Medical Sector

952nd out of 1,283 stocks

Pharmaceutical Preparations Industry

457th out of 615 stocks

See Top Rated MarketRank™ Stocks Here
Artelo Biosciences logo

About Artelo Biosciences (NASDAQ:ARTL) Stock

Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for prostate and breast cancer treatment, as well as for treating PTSD. Artelo Biosciences, Inc. has research collaboration with Trinity College Dublin to investigate ART27.13 for the treatment of cancer cachexia. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.

Receive ARTL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Artelo Biosciences and its competitors with MarketBeat's FREE daily newsletter.

ARTL Stock News Headlines

August 6, 2022 | finance.yahoo.com
Artelo Biosciences, Inc. (ARTL)
June 27, 2022 | msn.com
Artelo Biosciences Reveals Positive Pre-Clinical Results Of ART26.12, A Novel FABP5 Inhibitor, In Alleviating Chemotherapy-Induced Pain
June 27, 2022 | finance.yahoo.com
Artelo Biosciences Presents Positive Pre-Clinical Results of ART26.12, a Novel FABP5 Inhibitor, in Alleviating Chemotherapy-Induced Pain
June 24, 2022 | finance.yahoo.com
Artelo Biosciences Selected for Oral Presentation at the 32nd Annual ICRS Symposium in Galway, Ireland
June 3, 2022 | morningstar.com
Artelo Biosciences Inc - Stock News
May 14, 2022 | finanznachrichten.de
Artelo Biosciences, Inc.: Artelo Biosciences to Present at MicroCap Rodeo's Spring into Action Best Ideas Virtual Conference on May 16th
April 13, 2022 | seekingalpha.com
Artelo Biosciences stock soars 40% on pre-clinical data for ART27.13 in cancer-related muscle degeneration
April 13, 2022 | finance.yahoo.com
Artelo Biosciences Reports Positive Pre-clinical Results for Lead Program in Cancer-Related Cachexia
March 28, 2022 | finance.yahoo.com
Artelo Expands Collaboration with Trinity College Dublin to Investigate Cellular Biology of Fatty Acid Binding Protein (FABP) Inhibition In Cancer
March 23, 2022 | apnews.com
Artelo Biosciences to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest on March 28th – 30th
March 22, 2022 | finance.yahoo.com
Artelo Biosciences to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest on March 28th – 30th
March 21, 2022 | seekingalpha.com
Artelo Biosciences GAAP EPS of -$0.12
March 21, 2022 | finance.yahoo.com
Artelo Biosciences Reports Four-Month 2021 Financial Results in Connection with its Amended Fiscal Year End and Provides Business Update
March 10, 2022 | theglobeandmail.com
Instrument Name Artelo Biosciences Inc Instrument Symbol (ARTL-Q)
March 2, 2022 | finance.yahoo.com
Artelo Biosciences Receives Notice of Allowance for Method-of-Use Patent in the United States for ART12.11, a Proprietary Cocrystal of Cannabidiol
January 12, 2022 | seekingalpha.com
Artelo Biosciences GAAP EPS of -$0.08
January 12, 2022 | finance.yahoo.com
Artelo Biosciences Reports First Quarter Fiscal Year 2022 Financial Results and Provides Business Update
January 11, 2022 | finance.yahoo.com
Artelo Anticipates Accelerated Clinical Development for ART27.13 Following Its Classification Change in the United Kingdom
January 10, 2022 | finance.yahoo.com
Artelo Biosciences Leadership to Participate on Endocannabinoid Panel at the H.C. Wainwright BioConnect 2022 Virtual Conference
January 7, 2022 | nasdaq.com
Artelo Biosciences Inc Shares Close in on 52-Week Low - Market Mover
January 6, 2022 | msn.com
Is Artelo Biosciences, Inc. (ARTL) Stock Outpacing Its Medical Peers This Year?
January 6, 2022 | nasdaq.com
Artelo Biosciences Inc Shares Approach 52-Week Low - Market Mover
November 29, 2021 | finance.yahoo.com
Artelo Biosciences Reports Fiscal 2021 Year-End Financial Results and Provides Business Update
November 2, 2021 | finance.yahoo.com
We Think Artelo Biosciences (NASDAQ:ARTL) Needs To Drive Business Growth Carefully
September 17, 2021 | msn.com
BRIEF-Artelo Biosciences Says On September 13, Received Notice From Nasdaq Indicating Co Is Not In Compliance With Certain Nasdaq Listing Rule
See More Headlines

Receive ARTL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Artelo Biosciences and its competitors with MarketBeat's FREE daily newsletter.

ARTL Company Calendar

Last Earnings
5/12/2022
Today
8/07/2022
Next Earnings (Estimated)
8/08/2022
Fiscal Year End
12/31/2022
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ARTL
CUSIP
N/A
CIK
1621221
Web
www.artelobio.com
Phone
(858) 925-7049
Fax
N/A
Employees
4
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$3.50
High Stock Price Forecast
$4.00
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
+828.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($0.30)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-7,440,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-44.27%
Return on Assets
-42.81%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
28.10
Quick Ratio
28.10

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.67 per share
Price / Book
0.56

Miscellaneous

Outstanding Shares
42,300,000
Free Float
40,816,000
Market Cap
$15.95 million
Optionable
Not Optionable
Beta
1.76

Key Executives

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













ARTL Stock - Frequently Asked Questions

Should I buy or sell Artelo Biosciences stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Artelo Biosciences in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Artelo Biosciences stock.
View analyst ratings for Artelo Biosciences or view top-rated stocks.

What is Artelo Biosciences' stock price forecast for 2022?

2 Wall Street research analysts have issued twelve-month price targets for Artelo Biosciences' shares. Their ARTL stock forecasts range from $3.00 to $4.00. On average, they expect Artelo Biosciences' share price to reach $3.50 in the next year. This suggests a possible upside of 828.4% from the stock's current price.
View analysts' price targets for Artelo Biosciences or view top-rated stocks among Wall Street analysts.

How has Artelo Biosciences' stock performed in 2022?

Artelo Biosciences' stock was trading at $0.5190 on January 1st, 2022. Since then, ARTL shares have decreased by 27.4% and is now trading at $0.3770.
View the best growth stocks for 2022 here.

When is Artelo Biosciences' next earnings date?

Artelo Biosciences is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022.
View our earnings forecast for Artelo Biosciences.

How were Artelo Biosciences' earnings last quarter?

Artelo Biosciences, Inc. (NASDAQ:ARTL) issued its quarterly earnings data on Thursday, May, 12th. The company reported ($0.05) EPS for the quarter.

What other stocks do shareholders of Artelo Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Artelo Biosciences investors own include NVIDIA (NVDA), VBI Vaccines (VBIV), Provention Bio (PRVB), Sorrento Therapeutics (SRNE), ADMA Biologics (ADMA), Flexion Therapeutics (FLXN), OPKO Health (OPK), Overstock.com (OSTK), Allena Pharmaceuticals (ALNA) and Advanced Micro Devices (AMD).

What is Artelo Biosciences' stock symbol?

Artelo Biosciences trades on the NASDAQ under the ticker symbol "ARTL."

How do I buy shares of Artelo Biosciences?

Shares of ARTL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Artelo Biosciences' stock price today?

One share of ARTL stock can currently be purchased for approximately $0.38.

How much money does Artelo Biosciences make?

Artelo Biosciences (NASDAQ:ARTL) has a market capitalization of $15.95 million. The company earns $-7,440,000.00 in net income (profit) each year or ($0.30) on an earnings per share basis.

How many employees does Artelo Biosciences have?

Artelo Biosciences employs 4 workers across the globe.

How can I contact Artelo Biosciences?

Artelo Biosciences' mailing address is 888 Prospect Street Suite 210, La Jolla CA, 92037. The official website for Artelo Biosciences is www.artelobio.com. The company can be reached via phone at (858) 925-7049 or via email at artl@crescendo-ir.com.

This page (NASDAQ:ARTL) was last updated on 8/7/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits Financial Juice YouTube

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.